OncoMatch/Clinical Trials/NCT05842707
Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma
Is NCT05842707 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies dualCAR-NK19/70 cell for refractory or relapsed b-cell non-hodgkin lymphoma.
Treatment: dualCAR-NK19/70 cell — To find the highest tolerable dose of dualCAR-NK19/70 (a type of cell therapy) that can be given to patients who have B-cell lymphoma that is relapsed or refractory.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 overexpression (CD19+)
Previously confirmed diagnosis as CD19+ or CD70+ B-NHL
Required: CD70 overexpression (CD70+)
Previously confirmed diagnosis as CD19+ or CD70+ B-NHL
Performance status
ECOG 0–3(Limited self-care)
Demographics
Prior therapy
Must have received: immunotherapy or chemotherapy
Relapsed or Refractory DLBCL and tFL after 2 lines Immunotherapy or chemotherapy
Must have received: immunotherapy or chemotherapy
disease progression after more than 4 courses of standard Immunotherapy or chemotherapy
Must have received: autologous hematopoietic stem cell transplantation
disease progression or recurrence within 12 months after autologous hematopoietic stem cell transplantation (auto-HSCT)
Must have received: immune chemotherapy
Relapsed or Refractory MCL must be 1 line with immune chemotherapy
Must have received: BTK inhibitor
BTK inhibitors are resistant or intolerant as 2-line therapy
Must have received: chemotherapy including rituximab and anthracycline (rituximab, anthracycline)
Relapsed or Refractory disease after chemotherapy including rituximab and anthracycline
Must have received: CAR-T cell therapy
Either having failed or Relapsed after CAR-T therapy at 3 months of assessment
Lab requirements
Blood counts
ANC > 1000/μL, Platelet count > 45,000/μL, Hemoglobin > 80g/L
Kidney function
creatinine clearance > 60 mL/min; glomerular filtration rate > 50 ml/min
Liver function
ALT/AST ≤2.5x ULN for age; total bilirubin and alkaline phosphatase ≤1.5x ULN for age
Cardiac function
ejection fraction (EF) ≥ 45% by ECHO or MUGA
Adequate reserve of organ function: (A) Serum ALT/AST ≤2.5x ULN for age; (B) creatinine clearance > 60mL/min; (C) total bilirubin and alkaline phosphatase ≤1.5x ULN for age; (D) glomerular filtration rate > 50 ml/min; (E) Cardiac ejection fraction (EF) ≥ 45% as determined by an echocardiogram (ECHO) or Multigated Radionuclide Angiography (MUGA); (F) Baseline oxygen saturation >92% on room air; (G) Absolute neutrophil count > 1000/μL, Platelet count > 45,000/μL, Hemoglobin > 80g/L
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05842707 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received immunotherapy or chemotherapy and immunotherapy or chemotherapy.
Does this trial require CD19?
Yes, CD19 overexpression is a required biomarker for enrollment.
Does this trial require CD70?
Yes, CD70 overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages